Antarctica

The growth of predictive data analytics and the simultaneous growth in the availability of interoperable AI-enabled devices offer opportunities to mitigate healthcare disparities currently endemic in indigent, underrepresented, and underserved communities supporting SDG3.
Elsevier,

Genomic Data Sharing,  Case Studies, Challenges, and Opportunities for Precision Medicine, 2023, Pages 71-90

 

The Global Alliance for Genomics and Health (GA4GH) is an international standards development organization focused on advancing human health and medicine through genomic data sharing and interoperability. Founded in 2013, the organization has evolved over time and has adapted to unexpected challenges. Three themes have emerged as critical to the organization's success: (1) community needs must drive development; (2) agility is necessary to create global equity and opportunity; (3) developing an idea into a widely adopted standard requires multiple levels of consensus furthering SDG3.
With the aging global population, the relationship between older people and their residential environments is increasingly important. This relationship is based on the match between the individual characteristics of a person, their needs and expectations, and the characteristics of their environment. By creating access to various health improvement factors and exposure to various risk factors, the conditions under which an individual ages can be modified. This helps to accelerate or decelerate the process of incapacitation that individuals undergo as they age. This can also reduce or reinforce socio-spatial inequalities, which underlie the preponderant role of territory and spatial policies in the prevention and promotion of healthy aging. This chapters supports the process for developing the Decade of Healthy Ageing (2020 – 2030) aligned to the Sustainable Development Goals (SDG3).

An estimated 50 million people around the world currently live with Alzheimer's disease or other dementias, dementia being a collective term for progressive syndromes that affect various expressions of cognitive function, such as memory and emotional expression. Alzheimer’s disease accounts for the majority of cases (50 to 70%, varying by country, based on Alzheimer’s Disease International and World Health Organization figures).

This book chapter advances SDG #3 and #10 by focusing on an emblematic delayed-onset pathology often seen after traumatic brain injury—Alzheimer’s disease—and explain its relationship with chronic traumatic encephalopathy.
This book chapter advances SDG #3 and #10 by focusing on polyphenols and flavonoids and their crucial role in decreasing AD symptoms. In addition, it highlights the neuroprotective role of various essential ingredients of plant extracts such as Icariside, Onjisaponin B, Asarones, Liquiritin, Tanshinone IIA (TIIA) and cryptotanshinone (CT), Ginsenoside Rg1, and n-Butylidenephthalide. The efficacy of green nanotechnology are also discussed.

Exercise to Prevent and Manage Chronic Disease Across the Lifespan, 2022, Pages 413-421

This book chapter advances SDG #3 and #10 by outlining the pathophysiology associated with Alzheimer’s disease and provide an overview of the impact of exercise programs on cognition, physical functional abilities, behavioral, and psychological symptoms and quality of life.

Neurobiology of Brain Disorders (Second Edition), Biological Basis of Neurological and Psychiatric Disorders, 2022, Pages 313-336

This book chapter advances SDG #3 and #10 by reviewing several key topics that influence our understanding of pathogenic mechanisms and lead to the identification of novel therapeutic strategies. These include the diagnostic spectrum of MCI and AD, genetic risk alleles associated with late-onset AD, structures of gamma-secretase and tau, imaging and fluid biomarkers, the role of microglia and neuroinflammation, and novel animal models of AD.
This book chapter advances SDG #3 and #10 by presenting drug delivery systems based on nanotechnology to treat Alzheimer’s disease.
This book chapter advances SDG #3 and #10 by highlighting a few newly updated nano drug delivery technologies implemented in Alzheimer’s disease therapies and prospects for the future regarding potential molecular mechanisms of nano drug delivery methods

Pages